Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Grade 1</td><td align="left">Macular or papular rash or erythema but no other associated symptoms</td><td align="left"> </td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left" rowspan="2">
								Grade 2</td><td align="left">Grade 2A<br/></td><td align="left">Grade 1 + pruritis or other symptoms which are tolerable <br/></td></tr><tr><td align="left">Grade 2B<br/></td><td align="left">Grade + pruritis or other symptoms which interfere with daily life<br/></td></tr><tr><td align="left" colspan="3"><hr/></td></tr><tr><td align="left">Grade 3</td><td align="left" colspan="2">Severe, generalised erythroderma, or macular, popular, or vesicular eruption <br/></td></tr><tr><td align="left" colspan="3"><hr/></td></tr><tr><td align="left">Grade 4</td><td align="left" colspan="2">Generalized exfoliative, ulcerative, or blistering skin toxicity <br/></td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>


						Parmar  et al. modified EGFRI rash grading system [<a href="/journals/cherp/2012/351210/#B31">31</a>].

Chemotherapy Research and Practice

tab1

Table 1

Table 1: Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management 